JW (Cayman) Therapeutics Co. Ltd (HKG:2126)

Hong Kong · Delayed Price · Currency is HKD

2.250

+0.100 (4.65%)

Aug 27, 2026, 4:08 PM HKT

-63.11% (1Y)

Market Cap	872.67M -64.7%
Revenue (ttm)	315.65M +79.3%
Net Income	-617.93M
EPS	-1.49
Shares Out	405.90M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,398,000
Open	2.150
Previous Close	2.150
Day's Range	2.120 - 2.250
52-Week Range	1.400 - 6.100
Beta	1.92
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About HKG:2126

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People’s Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. It offers Carteyva, JWCAR201, and JWCAR239 for the treatment of hematological malignancies, advanced relmacabtagene autoleucel injection (“relma-cel”) as a potential treatment for systemic lupus eryth... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2016

Employees 314

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2126

Full Company Profile

Financial Performance

In 2025, HKG:2126's revenue was 283.65 million, an increase of 79.28% compared to the previous year's 158.22 million. Losses were -555.29 million, -5.98% less than in 2024.

Financial numbers in CNY Financial Statements